Issue Date: March 9, 2009
BMS Links With Japanese Firms
Bristol-Myers Squibb is collaborating with the Japanese companies Nissan Chemical Industries and Teijin Pharma to develop Nissan’s NTC-801 outside Japan. Teijin already has Japanese rights. A selective inhibitor of the acetylcholine-activated potassium ion channel, NTC-801 is currently in Phase I development in Japan for treating a form of arrhythmia. BMS will pay $40 million up front and potentially make milestone payments of up to $170 million.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society